Cell Therapy Raw Materials Market Size, Analysis and Forecast 2034
Global Cell Therapy Raw Materials Market Growth, Size, Trends Analysis - By Product, By End-use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25242 | Pages: 1 - 269 | Formats*: |
| Category : Healthcare | |||
Global Cell Therapy Raw Materials Market Introduction and Overview
According to SPER Market Research, the Global Cell Therapy Raw Materials Market is estimated to reach USD 24.78 billion by 2034 with a CAGR of 18.16%.
The report includes an in-depth analysis of the Global Cell Therapy Raw Materials, including market size and trends, product mix, Applications, and supplier analysis. The Cell Therapy Raw Materials Market was valued at USD 4.67 billion in 2024 and is expected to grow at a CAGR of 18.16% from 2025 to 2034. Over the projected period, the market is likely to be driven by innovations in cell culture goods such as medium and sera, as well as the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. Cell therapy has enormous potential for treating various illnesses, and as a result, there is an increasing need for the raw materials used in the development of cell-based medicines.
By Product Insights
The market is divided into several product categories, including medium, sera, cell culture supplements, antibodies, reagents and buffers, and others. The cell culture supplements category has a sizable market share due to the increased need for animal-free cell-based medicines. The segment is expected to experience continued growth, supported by ongoing innovations and business expansion efforts by key industry players. Numerous companies are exploring untapped opportunities and investing in the development of advanced supplements to meet the evolving needs of cell therapy applications. This trend reflects the broader shift in the industry toward safer, more effective, and ethically compliant raw material solutions.
By End-use Insights
The market is divided into three segments based on end use: biopharmaceutical and pharmaceutical firms, CMOs and CROs, and others. The biopharmaceutical and pharmaceutical firms segment dominates the market due to rising acknowledgement of cell therapy's ability to revolutionise treatment for a variety of diseases, including cancer, autoimmune disorders, and degenerative conditions. These firms are increasing their investment in the research, development, and commercialisation of cell-based medicines, which is fuelling demand for high-grade raw materials. Their commitment to innovation and therapeutic progress continues to drive the growth and expansion of the cell therapy raw materials market.
Regional Insights
North America dominates the cell therapy raw materials industry, owing to the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular disease. This growing health burden has increased demand for novel cell-based therapies that provide sophisticated therapy choices for illnesses with few alternatives. As a result, the need for high-quality raw materials has increased, bolstering research, development, and manufacturing efforts throughout the region. A large presence of established biotech companies, modern healthcare infrastructure, and active research programs all contribute to the region's market leadership, positioning it as a vital focus for cell therapy development.
Market Competitive Landscape
Several significant businesses dominate the cell therapy raw materials market, each capitalising on unique characteristics to lead the sector. Thermo Fisher Scientific Inc. distinguishes out for its diverse product line and global manufacturing capabilities, making it a trusted supplier of dependable and scalable solutions. Merck KGaA leads with its high-quality GMP-grade components, which are required for clinical and commercial cell therapy production Danaher, through Cytiva and Pall Life Sciences, specialises in advanced bioprocessing technology. Sartorius Stedim Biotech dominates with its breakthroughs in single-use solutions.
Recent Developments:
In December 2024, BioCentriq negotiated a long-term lease for a new production facility in Princeton, New Jersey, which will serve as its headquarters. The USD 12 million investment will strengthen its skills in cell therapy development and manufacture.
In October 2024, Thermo Fisher Scientific opened a bioprocess design centre in Genome Valley, Hyderabad. This change reflects increasing market demand.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By End-use |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | ACROBiosystems, Actylis, Charles River Laboratories, Danaher, Grifols S.A., Merck KGaA, Promo Cell GmbH, Rooster Bio Inc., Sartorius Stedim Biotech, STEMCELL Technologies, Thermo Fisher Scientific Inc |
Key Topics Covered in the Report
- Global Cell Therapy Raw Materials Market Size (FY’2021-FY’2034)
- Overview of Global Cell Therapy Raw Materials
- Segmentation of Global Cell Therapy Raw Materials Market by Controlling Method (Media, Sera, Cell Culture Supplements, Antibodies, Reagents & Buffers, Others)
- Segmentation of Global Cell Therapy Raw Materials Market by Application (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, Others)
- Statistical Snap of Global Global Cell Therapy Raw Materials
- Expansion Analysis of Global Cell Therapy Raw Materials Market
- Problems and Obstacles in Global Cell Therapy Raw Materials Market
- Competitive Landscape in the Global Cell Therapy Raw Materials Market
- Problems and Obstacles in Global Cell Therapy Raw Materials
- Competitive Landscape in the Global Cell Therapy Raw Materials
- Details on Current Investment in Global Cell Therapy Raw Materials
- Competitive Analysis of Global Cell Therapy Raw Materials
- Prominent Players in the Global Cell Therapy Raw Materials
- SWOT Analysis of Global Cell Therapy Raw Materials
- Global Cell Therapy Raw Materials Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Cell Therapy Raw Materials Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Smart Shower Market
7.Global Cell Therapy Raw Materials Market, By Product (USD Million) 2021-2034
7.1.Media7.2.Sera7.3.Cell Culture Supplements7.4.Antibodies7.5.Reagents & Buffers7.6.Others
8.Global Cell Therapy Raw Materials Market, By End-use (USD Million) 2021-2034
8.1.Biopharmaceutical & Pharmaceutical Companies8.2.CROs & CMOs8.3.Others
9.Global Cell Therapy Raw Materials Market, (USD Million) 2021-2034
9.1.Global Cell Therapy Raw Materials Market Size and Market Share
10.Global Smart Shower Market, By Region, (USD Million) 2021-2034
10.1.Asia-Pacific
10.1.1.Australia10.1.2.China10.1.3.India10.1.4.Japan10.1.5.South Korea10.1.6.Rest of Asia-Pacific
10.2.Europe
10.2.1.France10.2.2.Germany10.2.3.Italy10.2.4.Spain10.2.5.United Kingdom10.2.6.Rest of Europe
10.3.Middle East and Africa
10.3.1.Kingdom of Saudi Arabia10.3.2.United Arab Emirates10.3.3.Qatar10.3.4.South Africa10.3.5.Egypt10.3.6.Morocco10.3.7.Nigeria10.3.8.Rest of Middle East and Africa
10.4.North America
10.4.1.Canada10.4.2.Mexico10.4.3.United States
10.5.Latin America
10.5.1.Argentina10.5.2.Brazil10.5.3.Rest of Latin America
11.Company Profile
11.1.ACRO Biosystems
11.1.1.Company details11.1.2.Financial outlook11.1.3.Product summary11.1.4.Recent developments
11.2.Actylis
11.2.1.Company details11.2.2.Financial outlook11.2.3.Product summary11.2.4.Recent developments
11.3.Charles River Laboratories
11.3.1.Company details11.3.2.Financial outlook11.3.3.Product summary11.3.4.Recent developments
11.4.Danaher
11.4.1.Company details11.4.2.Financial outlook11.4.3.Product summary11.4.4.Recent developments
11.5.Grifols, S.A.
11.5.1.Company details11.5.2.Financial outlook11.5.3.Product summary11.5.4.Recent developments
11.6.Merck KGaA
11.6.1.Company details11.6.2.Financial outlook11.6.3.Product summary11.6.4.Recent developments
11.7.Promo Cell GmbH
11.7.1.Company details11.7.2.Financial outlook11.7.3.Product summary11.7.4.Recent developments
11.8.Rooster Bio, Inc.
11.8.1.Company details11.8.2.Financial outlook11.8.3.Product summary11.8.4.Recent developments
11.9.Sartorius Stedim Biotech
11.9.1.Company details11.9.2.Financial outlook11.9.3.Product summary11.9.4.Recent developments
11.10.STEMCELL Technologies
11.10.1.Company details11.10.2.Financial outlook11.10.3.Product summary11.10.4.Recent developments
11.11.Others
12.Conclusion
13.List of Abbreviations
14.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Cell Therapy Raw Materials Market is projected to reach USD 24.78 billion by 2034, growing at a CAGR of 18.16% during the forecast period.
Cell Therapy Raw Materials Market size from 2025. The Market is expected to reach USD 24.78 billion by 2034, at a CAGR of 18.16% during the forecast period.
Cell Therapy Raw Materials Market CAGR of 18.16% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Cell Therapy Raw Materials Market size is USD 24.78 billion from 2025 to 2034.
Cell Therapy Raw Materials Market covered By Product, By End-use
The North America is anticipated to have the highest Market share in the Cell Therapy Raw Materials Market.
ACROBiosystems, Actylis, Charles River Laboratories, Danaher, Grifols S.A., Merck KGaA, Promo Cell GmbH, Rooster Bio Inc., Sartorius Stedim Biotech, STEMCELL Technologies, Thermo Fisher Scientific Inc
The report includes an in-depth analysis of the Global Cell Therapy Raw Materials, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
